Gaucher Disease Genetics and Inheritance

Gaucher disease is caused by a deficiency of the lysosomal enzyme acid β-glucosidase (also known as glucocerebrosidase). The enzymatic deficiency leads to an accumulation of glucosylceramide (also known as GL-1) in the lysosomes.¹

Gaucher disease is a rare, autosomal recessive condition affecting all ethnicities, with a higher prevalence of Gaucher disease type 1 in Ashkenazi Jews.²

Screening can prompt an early diagnosis and treatment initiation, which can help to get ahead of irreversible complications from the disease.^3-5

Epidemiology of Gaucher Disease

Gaucher disease is a rare disease with an estimated incidence of 0.39 to 5.80 per 100,000 individuals and a prevalence between 0.70 and 1.75 per 100,000.⁴

The disease is classified into 3 subtypes, which differ in their presentation and disease severity.² The different types of Gaucher disease are not equally distributed across various ethnic groups.² Knowledge of which individuals might have a higher risk of Gaucher disease is critical to identifying patients who would benefit from testing.⁴

Gaucher Disease in the Ashkenazi Jewish Population

Ninety percent of Jewish Americans are Ashkenazi.⁶ Gaucher disease type 1 occurs most often in people of Ashkenazi Jewish heritage, affecting about 1 in 850 Ashkenazi Jewish people.⁷

In particular, one gene variant (N409S, previously known as N370S) found in the Ashkenazi Jewish population can cause skeletal disease, while not showing other typical disease symptoms.^7,8

Testing for Ashkenazi Jewish patients with enlarged spleen (splenomegaly) or low platelet count (thrombocytopenia), even in the absence of additional symptoms, is therefore especially encouraged for this patient group.^3,4,7

Inheritance Pattern of Gaucher Disease

Carriers of Gaucher disease only inherit 1 pathogenic variant in the GBA1 gene and are asymptomatic, but can pass on the disease to their children.^2,9 Gaucher disease usually occurs when an individual inherits 2 pathogenic variants within the GBA1 gene, one from each parent.^2,9 The disease can be passed down to children in the following ways^2,9:

^aThe probability of having a child with Gaucher disease does not change, no matter how many children the parents have.

GBA1 Gene Variants in Gaucher Disease

The GBA1 gene encodes the acid β-glucosidase (also known as glucocerebrosidase), which plays a vital role in lipid metabolism.¹ The enzyme resides mainly in the lysosome, where it breaks down glucosylceramide (also known as GL-1) into glucose and ceramide.¹⁰

Pathogenic variants in the GBA1 gene, and consequently a disrupted function of acid β-glucosidase (also known as glucocerebrosidase), cause a buildup of the enzyme's substrate. Glucosylceramide accumulation in cells of the liver, spleen, and bone marrow leads to progressive multiorgan dysfunction and the symptoms of Gaucher disease.¹⁰

Over 400 pathogenic variants have been reported to cause Gaucher disease.^11,12 Frequently observed variants include N409S (c.1226A < G), 84GG (c.84dupG) and L483P (c.1448T > C ).⁸ These variants are unequally distributed across different populations.⁸

Some variants are more frequently associated with certain disease types; for instance, the N409S variant is associated with Gaucher disease type 1, whereas L483P is linked to type 2 and 3.⁸ Despite these observations, individuals carrying the same variants can show a heterogeneous clinical manifestation of Gaucher disease.^8,13 This indicates that other contributing factors influence the clinical presentation of the disease, such as the environment and epigenetic status of the person.¹³

Summary Table of Common GBA1 Variants by Population⁸

Screening Can Help Get Ahead of Gaucher Disease

Gaucher disease is almost always passed down from birth parents and may affect several members of a family within a single generation.⁹ Hence, it is important to direct family members to consider testing if their relative has been diagnosed with Gaucher disease. Genetic testing can confirm a diagnosis or that someone is a carrier for Gaucher disease.⁹ 

FAQs

What chromosome is affected in Gaucher disease? 

The pathogenic variants responsible for Gaucher disease are found on chromosome 1 (1q21), where the gene for acid β-glucosidase (also known as glucocerebrosidase) is located.²

What type of pathogenic variants cause Gaucher disease?

Pathogenic variants in the GBA1 gene lead to Gaucher disease. The condition can be caused by a variety of genetic rearrangements, including missense mutations, nonsense mutations, frameshift mutations, splice-site mutations, insertions, and deletions.¹²

Is Gaucher disease recessive or dominant?

Gaucher disease is a hereditary autosomal recessive disease.²

Which populations are most affected by Gaucher disease?

Gaucher disease can affect all populations. However, Gaucher disease type 1 has the highest prevalence in individuals of Ashkenazi Jewish heritage, affecting about 1 in 850 Ashkenazi Jewish people.⁷

References: 1. Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18(2):441. doi:10.3390/ijms18020441 2. Alaei MR, Tabrizi A, Jafari N, Mozafari H. Gaucher disease: new expanded classification emphasizing neurological features. Iran J Child Neurol. 2019;13(1):7-24. Accessed August 1, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC6296697/ 3. Mehta A, Kuter DJ, Salek SS, et al. Presenting signs and patient co-variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED-C) Delphi initiative. Intern Med J. 2019;49(5):578-591. doi:10.1111/imj.14156 4. Kishnani PS, Al-Hertani W, Balwani M, et al. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Mol Genet Metab. 2022;135(2):154-162. doi:10.1016/j.ymgme.2021.12.009 5. Chaves RG, Coelho JC, Michelin-Tirelli K, et al. Successful screening for Gaucher disease in a high-prevalence population in tabuleiro do Norte (northeastern Brazil): a cross-sectional study. JIMD Rep. 2011;1:73-78. doi:10.1007/8904_2011_19 6. Strom CM, Crossley B, Redman JB, et al. Molecular screening for diseases frequent in Ashkenazi Jews: lessons learned from more than 100,000 tests performed in a commercial laboratory. Genetics in Medicine. 2004;6(3):145-152. doi:10.1097/01.GIM.0000127267.57526.D1 7. Mistry PK, Cappellini MD, Lukina E, et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 2011;86(1):110-115. doi:10.1002/ajh.21888 8. Riboldi GM, Di Fonzo AB. GBA, Gaucher disease, and Parkinson’s disease: from genetic to clinic to new therapeutic approaches. Cells. 2019;8(4):364. doi:10.3390/cells8040364 9. Hughes DA, Pastores GM. Gaucher disease. In: GeneReviews^®. University of Washington, Seattle; 1993. Accessed July 29, 2025. https://www.ncbi.nlm.nih.gov/books/NBK1269/ 10. Boer DEC, van Smeden J, Bouwstra JA, Aerts JMFG. Glucocerebrosidase: functions in and beyond the lysosome. J Clin Med. 2020;9(3):736. doi:10.3390/jcm9030736 11. Tayebi N, Lichtenberg J, Hertz E, Sidransky E. Is Gauchian genotyping of GBA1 variants reliable? Commun Biol. 2025;8(1):718. doi:10.1038/s42003-025-08059-y 12. Dardis A, Michelakakis H, Rozenfeld P, et al. Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet J Rare Dis. 2022;17(1):442. doi:10.1186/s13023-022-02573-6 13. Davidson BA, Hassan S, Garcia EJ, Tayebi N, Sidransky E. Exploring genetic modifiers of Gaucher disease: the next horizon. Hum Mutat. 2018;39(12):1739-1751. doi:10.1002/humu.23611